Company research
Fetched today
SpectaCell builds a fast, label-free single-cell analysis platform that helps biopharma developers and specialist manufacturers measure how immune therapies affect individual cells from early R&D through manufacturing.
- Founders
- Tony Montoye · CEO and co-founder
- Veronique De Vroey
- Mathieu Rabaey · Co-Founder and Head of ProductBefore SpectaCell, he worked at Antelope Dx, Unchained Labs, TRINEAN and the Photonics Research Group at Ghent University-imec.
- Jan Van de Velde
- Total raised
- €6,000,000 · as its sources put it, more than the rounds on record
WHY IT MATTERS
SpectaCell is addressing a drug-development blind spot: existing tests can rely on indirect signals or averages that hide how individual cells respond, while its chip-based, label-free platform is designed to deliver richer results within hours and connect research with manufacturing quality checks. Its €6 million seed round, led by imec.xpand, funds further platform development and commercialization, backing the company’s bet that a common measurement workflow can reduce testing delays and costs and help better immune therapies reach patients sooner.